EMA Pediatric Committee Adopts Positive Opinion on Peanut Allergy Treatment for Children
The pediatric investigation plan provides a clinical development plan for Viaskin Peanut in pediatric population. DBV Technologies will now be able to submit a marketing authorization application in Europe following completion of the Viaskin Peanut Phase III trials.
Biopharmaceutical company DBV Technologies announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has adopted a positive opinion on the company's pediatric investigation plan for Viaskin Peanut for the treatment of peanut allergy in children.
The European regulatory framework requires pharmaceutical companies to provide a pediatric investigation plan outlining their strategy for assessing new medicinal products in children. Acceptance of the pediatric investigation plan is a prerequisite for the filing a marketing authorization application for a new medicinal product in Europe.
The pediatric investigation plan provides a clinical development plan for Viaskin Peanut in pediatric population from 1 to 17 years of age, in particular the details of the Phase III trials. DBV Technologies will now be able to submit a marketing authorization application in Europe following completion of the Viaskin Peanut Phase III trials.
Viaskin Peanut is an electrostatic patch, based on epicutaneous immunotherapy (EPIT), which delivers an allergen onto the skin. Antigen-presenting cells are targeted to activate the immune system without allowing passage of the antigen into the bloodstream. The patch has shown good safety profile in past and ongoing studies.
Source: DBV Technologies
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
